MYD88 and hepatocellular carcinoma: Inhibition of the binding of CacyBP-MyD88 could reduce fractalkine (CX3CL1) secretion and thus weaken the recruitment of tumor-associated macrophages (TAMs) to the immune microenvironment, making hepatocellular carcinoma mice sensitive to programmed death 1 (PD-1) treatment [50].